Capacity of advanced glycosidation end products in patients on hemodialysis

Advanced glycation endproducts (AGEs) are formed during non-enzymatic glycation and oxidation reactions. Acidic β2-MG in amyloid fibrils of patients with dialysis related amyloidosis contained early Amadori products and AGEs. In the present study, we measured serum AGEs levels by enzyme-linked immunosorbent assays (ELISA) before and after hemodialysis (HD), and examined the changes in serum AGE levels during a single session of HD therapy, and whether serum AGE level was influenced by the type of dialyzer or not. Ninety-five patients on HD were included in this study. We used high-flux dialyzers such as cellulose triacetate or polysulfone dialyzers, and low-flux dialyzers such as ethylene vinyl alcohol or regenerated cellulose (RC) dialyzers. We measured serum level of AGE and the capacity of AGEs production contained both early Amadori products and AGE. Serum AGEs level was significantly decreased during HD. The reduction rate in serum AGEs level with high-flux dialyzers was higher than that with low-flux dialyzers. The capacity of AGEs production before HD in high-flux dialyzers showed less than those with RC dialyzers. Moreover, the capacity of AGEs production correlated positively with indices of glycemic control. In conclusion, the reduction rates of serum AGE levels in high-flux dialyzers were higher than that with low-flux dialyzers. The capacity of AGEs production might be dependent upon the characteristics of dialysis membrane materials. Furthermore, as the capacity of AGEs production was correlated with indices of glycemic control, the production of early Amadori products might partly associated with hyperglycemia.